Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

Suárez García, Inés
Alejos, Belén
Hernando, Victoria
Viñuela, Laura
Vera García, Mar
Rial Crestelo, David
Pérez Elías, María Jesús
Albendín Iglesias, Helena
Peraire, Joaquim
Spanish HIV/AIDS Research Network (CoRIS)
Et al.

Open link

Publication date

January 2023

DOI

10.1093/jac/dkad102

Journal

Journal of Antimicrobial Chemotherapy

Abstract

Objectives To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) among treatment-naive and virologically suppressed treatment-experienced individuals in the multicentre cohort of the Spanish HIV/AIDS Research Network (CoRIS) during the years 2018–2021. Methods We used multivariable regression models to compare viral suppression (VS) [HIV RNA viral load (VL) <50 copies/mL] and the change in CD4 cell counts at 24 and 48 (±12) weeks after initiation with dolutegravir/lamivudine or other first-line ART regimens. Results We included 2160 treatment-naive subjects, among whom 401 (18.6%) started with dolutegravir/lamivudine. The remaining subjects started bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafen...

Extracted data

We use cookies to provide a better user experience.

Data Protection

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

Suárez García, Inés
Alejos, Belén
Hernando, Victoria
Viñuela, Laura
Vera García, Mar
Rial Crestelo, David
Pérez Elías, María Jesús
Albendín Iglesias, Helena
Peraire, Joaquim
Spanish HIV/AIDS Research Network (CoRIS)
Et al.

Open link

Publication date

January 2023

DOI

10.1093/jac/dkad102

Journal

Journal of Antimicrobial Chemotherapy

Abstract

Extracted data

Topics

abacavirChemical substance

Carlos IIIPerson

lamivudineChemical substance

elvitegravirChemical substance

ABCAgent

AIDSDisease

viral load

RNAChemical compound

bictegravirChemical substance

tenofovir alafenamideChemical substance

HIVDisease

adverse event

SidaAgent

darunavirChemical substance

CD4Biomolecule

emtricitabineChemical substance

dolutegravir/lamivudineChemical substance

cobicistatChemical substance

dolutegravirChemical substance

24 weeksWork

tenofovir disoproxil fumarate (TDF)Chemical substance

Hidalgo-Tenorio, Carmen
Pasquau, Juan
Vinuesa, David
Ferra, Sergio
Terrón, Alberto
SanJoaquín, Isabel
Payeras, Antoni
Martínez, Onofre Juan
López-Ruz, Miguel Ángel
Omar, Mohamed
de la Torre-Lima, Javier
López-Lirola, Ana
Palomares, Jesús
Blanco, José Ramón
Montero, Marta
García-Vallecillos, Coral

March 2022

Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a mu...

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice

Borghetti A.
Lombardi F.
Gagliardini R.
Baldin G.
Ciccullo A.
Moschese D.
Emiliozzi A.
Belmonti S.
Lamonica S.
Montagnani F.
Visconti E.
De Luca A. (ORCID:0000-0002-8311-6935)
Di Giambenedetto S. (ORCID:0000-0001-6990-5076)

January 2019

Background: Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as main...

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

Suárez García, Inés
Alejos, Belén
Hernando, Victoria
Viñuela, Laura
Vera García, Mar
Rial Crestelo, David
Pérez Elías, María Jesús
Albendín Iglesias, Helena
Peraire, Joaquim
Spanish HIV/AIDS Research Network (CoRIS)
Et al.

January 2023

Objectives To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) amon...

Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.

Nasreddine, Rakan
Yombi, Jean Cyr
Darcis, Gilles
Florence, Eric
Allard, Sabine D
De Scheerder, Marie-Angélique
Henrard, Sophie
Demeester, Rémy
Messiaen, Peter
Ausselet, Nathalie
Loeckx, Matthias
Delforge, Marc
De Wit, Stéphane
Belgian Research on AIDS and HIV Consortium (BREACH)

January 2022

OBJECTIVES: A paradigm shift from three-drug regimens to two-drug regimens (2DRs) is currently takin...

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

Baldin G.
Ciccullo A.
Rusconi S.
Capetti A.
Sterrantino G.
Colafigli M.
d'Ettorre G.
Giacometti A.
Cossu M. V.
Borghetti A.
Gennari W.
Mussini C.
Borghi V.
Di Giambenedetto S.

January 2019

Background: Results from clinical trials and observational studies suggest that lamivudine plus dolu...

Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV

Ciccullo, A
Baldin, G
Borghi, V
Cossu, M V
Giacomelli, A
Lagi, F
Farinacci, D
Iannone, V
Passerotto, R A
Capetti, A
Sterrantino, G
Mussini, C
Antinori, S
Di Giambenedetto, S

January 2022

Objectives: We aimed to investigate and compare the efficacy and safety of two dolutegravir-based tw...

Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain

Suárez García, Ana
Alejos, Belén
Ruiz Algueró, Marta
García Yubero, Cristina
Moreno, Cristina
Bernal, Enrique
Pérez Is, Laura
Zubero, Zuriñe
Zárraga Fernández, Miguel Alberto de
Samperiz Abad, Gloria
Jarrín, Inmaculada
Spanish HIV/AIDS Research Network (CoRIS)

January 2021

We aimed to assess the effectiveness and tolerability of dolutegravir (DTG), abacavir (ABC) and lami...

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

Mondi A.
Cozzi-Lepri A.
Tavelli A.
Rusconi S.
Vichi F.
Ceccherini-Silberstein F.
Calcagno A.
De Luca A.
Maggiolo F.
Marchetti G.
Antinori A.
d'Arminio Monforte A.
Andreoni M.
Castagna A.
Castelli F.
Cauda R.
Di Perri G.
Galli M.
Iardino R.
Ippolito G.
azzarin A.
Rezza G.
von Schloesser F.
Viale P.
Girardi E.
Lo Caputo S.
Mussini C.
Puoti M.
Perno C. F.
Balotta C.
Bandera A.
Bonora S.
Borderi M.
Capetti A.
Capobianchi M. R.
Cicalini S.
Cingolani A.
Cinque P.
Di Biagio A.
Gianotti N.
Gori A.
Guaraldi G.
Lapadula G.
Lichtner M.
Madeddu G.
Monno L.
Nozza S.
Quiros Roldan E.
Rossotti R.
Santoro M. M.
aracino A.
Sarmati L.
Fanti I.
Lorenzini P.
Rodano' A.
Macchia M.
Carletti F.
Carrara S.
Di Caro A.
Graziano S.
Petrone F.
Prota G.
Quartu S.
Truffa S.
Giacometti I. A.
Costantini A.
Barocci V.
Angarano G.
Fabrizio C.
Suardi C.
i V.
Verucchi G.
Castelnuovo F.
Minardi C.
Menzaghi B.
Abeli C.
Cacopardo B.
Celesia B.
Vecchiet J.
Falasca K.
Pan A.
Lorenzotti S.
Sighinolfi L.
Segala D.
Blanc P.
Cassola G.
Viscoli C.
lessandrini A.
Bobbio N.
Mazzarello G.
Pozzetto I.
Bonfanti P.
Molteni C.
Chiodera A.
Milini P.
Nunnari G.
Pellicano G.
Rizzardini G.
Bai F.
Moioli M. C.
Piolini R.
Ridolfo A. L.
Salpietro S.
Tincati C.
Puzzolante C.
Migliorino C.
Sangiovanni V.
Borgia G.
Esposito V.
Di Martino F.
Gentile I.
Maddaloni L.
Cattelan A. M.
Marinello S.
Cascio A.
Colomba C.
Baldelli F.
Schiaroli E.
Parruti G.
Sozio F.
Magnani G.
Ursitti M. A.
Cristaudo A.
Vullo V.
Acinapura R.
Baldin G.
Capozzi M.
Rivano Capparucia M.
Iaiani G.
atini A.
Mastrorosa I.
Plazzi M. M.
Savinelli S.
Vergori A.
Cecchetto M.
Viviani F.
Bagella P.
Rossetti B.
Fontana Del Vecchio R.
Francisci D.
Di Giuli C.
Caramello P.
Orofino G. C.
Sciandra M.
Bassetti M.
ondero A.
Pellizzer G.
Manfrin V.
Starnini G.
alungo A.

January 2019

Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently ...

Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.

Nasreddine, Rakan
Florence, Eric
Vandercam, Bernard
Moutschen, Michel
Goffard, Jean-Christophe
De Munter, Paul
Delforge, Marc
Marinus, Wouter
De Wit, Stéphane
Belgian Research on AIDS and HIV Consortium (BREACH)

January 2020

OBJECTIVE: To describe the treatment outcomes of patients receiving dolutegravir (DTG) in a 'real-wo...

Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study

Rossetti, Barbara
Baldin, Gianmaria
Sterrantino, Gaetana
Rusconi, Stefano
De Vito, Andrea
Giacometti, Andrea
Gagliardini, Roberta
Colafigli, Manuela
Capetti, Amedeo
d’Ettorre, Gabriella
Celani, Luigi
Lagi, Filippo
Ciccullo, Arturo
De Luca, Andrea
Di Giambenedetto, Simona
Madeddu, Giordano

January 2019

The aims were to describe efficacy and tolerability of regimens containing dolutegravir (DTG) in adv...

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).

Hidalgo-Tenorio, Carmen
Pasquau, Juan
Vinuesa, David
Ferra, Sergio
Terrón, Alberto
SanJoaquín, Isabel
Payeras, Antoni
Martínez, Onofre Juan
López-Ruz, Miguel Ángel
Omar, Mohamed
de la Torre-Lima, Javier
López-Lirola, Ana
Palomares, Jesús
Blanco, José Ramón
Montero, Marta
García-Vallecillos, Coral

March 2022

Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a mu...

Borghetti A.
Lombardi F.
Gagliardini R.
Baldin G.
Ciccullo A.
Moschese D.
Emiliozzi A.
Belmonti S.
Lamonica S.
Montagnani F.
Visconti E.
De Luca A. (ORCID:0000-0002-8311-6935)
Di Giambenedetto S. (ORCID:0000-0001-6990-5076)

January 2019

Background: Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as main...

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

Suárez García, Inés
Alejos, Belén
Hernando, Victoria
Viñuela, Laura
Vera García, Mar
Rial Crestelo, David
Pérez Elías, María Jesús
Albendín Iglesias, Helena
Peraire, Joaquim
Spanish HIV/AIDS Research Network (CoRIS)
Et al.

January 2023

Objectives To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) amon...

Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.

Nasreddine, Rakan
Yombi, Jean Cyr
Darcis, Gilles
Florence, Eric
Allard, Sabine D
De Scheerder, Marie-Angélique
Henrard, Sophie
Demeester, Rémy
Messiaen, Peter
Ausselet, Nathalie
Loeckx, Matthias
Delforge, Marc
De Wit, Stéphane
Belgian Research on AIDS and HIV Consortium (BREACH)

January 2022

OBJECTIVES: A paradigm shift from three-drug regimens to two-drug regimens (2DRs) is currently takin...

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

Baldin G.
Ciccullo A.
Rusconi S.
Capetti A.
Sterrantino G.
Colafigli M.
d'Ettorre G.
Giacometti A.
Cossu M. V.
Borghetti A.
Gennari W.
Mussini C.
Borghi V.
Di Giambenedetto S.

January 2019

Background: Results from clinical trials and observational studies suggest that lamivudine plus dolu...

Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV

Ciccullo, A
Baldin, G
Borghi, V
Cossu, M V
Giacomelli, A
Lagi, F
Farinacci, D
Iannone, V
Passerotto, R A
Capetti, A
Sterrantino, G
Mussini, C
Antinori, S
Di Giambenedetto, S

January 2022

Objectives: We aimed to investigate and compare the efficacy and safety of two dolutegravir-based tw...

Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain

Suárez García, Ana
Alejos, Belén
Ruiz Algueró, Marta
García Yubero, Cristina
Moreno, Cristina
Bernal, Enrique
Pérez Is, Laura
Zubero, Zuriñe
Zárraga Fernández, Miguel Alberto de
Samperiz Abad, Gloria
Jarrín, Inmaculada
Spanish HIV/AIDS Research Network (CoRIS)

January 2021

We aimed to assess the effectiveness and tolerability of dolutegravir (DTG), abacavir (ABC) and lami...

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

Mondi A.
Cozzi-Lepri A.
Tavelli A.
Rusconi S.
Vichi F.
Ceccherini-Silberstein F.
Calcagno A.
De Luca A.
Maggiolo F.
Marchetti G.
Antinori A.
d'Arminio Monforte A.
Andreoni M.
Castagna A.
Castelli F.
Cauda R.
Di Perri G.
Galli M.
Iardino R.
Ippolito G.
azzarin A.
Rezza G.
von Schloesser F.
Viale P.
Girardi E.
Lo Caputo S.
Mussini C.
Puoti M.
Perno C. F.
Balotta C.
Bandera A.
Bonora S.
Borderi M.
Capetti A.
Capobianchi M. R.
Cicalini S.
Cingolani A.
Cinque P.
Di Biagio A.
Gianotti N.
Gori A.
Guaraldi G.
Lapadula G.
Lichtner M.
Madeddu G.
Monno L.
Nozza S.
Quiros Roldan E.
Rossotti R.
Santoro M. M.
aracino A.
Sarmati L.
Fanti I.
Lorenzini P.
Rodano' A.
Macchia M.
Carletti F.
Carrara S.
Di Caro A.
Graziano S.
Petrone F.
Prota G.
Quartu S.
Truffa S.
Giacometti I. A.
Costantini A.
Barocci V.
Angarano G.
Fabrizio C.
Suardi C.
i V.
Verucchi G.
Castelnuovo F.
Minardi C.
Menzaghi B.
Abeli C.
Cacopardo B.
Celesia B.
Vecchiet J.
Falasca K.
Pan A.
Lorenzotti S.
Sighinolfi L.
Segala D.
Blanc P.
Cassola G.
Viscoli C.
lessandrini A.
Bobbio N.
Mazzarello G.
Pozzetto I.
Bonfanti P.
Molteni C.
Chiodera A.
Milini P.
Nunnari G.
Pellicano G.
Rizzardini G.
Bai F.
Moioli M. C.
Piolini R.
Ridolfo A. L.
Salpietro S.
Tincati C.
Puzzolante C.
Migliorino C.
Sangiovanni V.
Borgia G.
Esposito V.
Di Martino F.
Gentile I.
Maddaloni L.
Cattelan A. M.
Marinello S.
Cascio A.
Colomba C.
Baldelli F.
Schiaroli E.
Parruti G.
Sozio F.
Magnani G.
Ursitti M. A.
Cristaudo A.
Vullo V.
Acinapura R.
Baldin G.
Capozzi M.
Rivano Capparucia M.
Iaiani G.
atini A.
Mastrorosa I.
Plazzi M. M.
Savinelli S.
Vergori A.
Cecchetto M.
Viviani F.
Bagella P.
Rossetti B.
Fontana Del Vecchio R.
Francisci D.
Di Giuli C.
Caramello P.
Orofino G. C.
Sciandra M.
Bassetti M.
ondero A.
Pellizzer G.
Manfrin V.
Starnini G.
alungo A.

January 2019

Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently ...

Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.

Nasreddine, Rakan
Florence, Eric
Vandercam, Bernard
Moutschen, Michel
Goffard, Jean-Christophe
De Munter, Paul
Delforge, Marc
Marinus, Wouter
De Wit, Stéphane
Belgian Research on AIDS and HIV Consortium (BREACH)

January 2020

OBJECTIVE: To describe the treatment outcomes of patients receiving dolutegravir (DTG) in a 'real-wo...

Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study

Rossetti, Barbara
Baldin, Gianmaria
Sterrantino, Gaetana
Rusconi, Stefano
De Vito, Andrea
Giacometti, Andrea
Gagliardini, Roberta
Colafigli, Manuela
Capetti, Amedeo
d’Ettorre, Gabriella
Celani, Luigi
Lagi, Filippo
Ciccullo, Arturo
De Luca, Andrea
Di Giambenedetto, Simona
Madeddu, Giordano

January 2019

The aims were to describe efficacy and tolerability of regimens containing dolutegravir (DTG) in adv...

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).

Hidalgo-Tenorio, Carmen
Pasquau, Juan
Vinuesa, David
Ferra, Sergio
Terrón, Alberto
SanJoaquín, Isabel
Payeras, Antoni
Martínez, Onofre Juan
López-Ruz, Miguel Ángel
Omar, Mohamed
de la Torre-Lima, Javier
López-Lirola, Ana
Palomares, Jesús
Blanco, José Ramón
Montero, Marta
García-Vallecillos, Coral

March 2022

Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a mu...

Borghetti A.
Lombardi F.
Gagliardini R.
Baldin G.
Ciccullo A.
Moschese D.
Emiliozzi A.
Belmonti S.
Lamonica S.
Montagnani F.
Visconti E.
De Luca A. (ORCID:0000-0002-8311-6935)
Di Giambenedetto S. (ORCID:0000-0001-6990-5076)

January 2019

Background: Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as main...

Topics

abacavirChemical substance

Carlos IIIPerson

lamivudineChemical substance

elvitegravirChemical substance

ABCAgent

AIDSDisease

viral load

RNAChemical compound

bictegravirChemical substance

tenofovir alafenamideChemical substance

HIVDisease

adverse event

SidaAgent

darunavirChemical substance

CD4Biomolecule

emtricitabineChemical substance

dolutegravir/lamivudineChemical substance

cobicistatChemical substance

dolutegravirChemical substance

24 weeksWork

tenofovir disoproxil fumarate (TDF)Chemical substance

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

Abstract

Extracted data

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

Abstract

Extracted data

Topics

Related items

Related items

Topics